0.65Open1.00Pre Close3 Volume411 Open Interest300.00Strike Price229.00Turnover41.56%IV22.84%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier27DDays to Expiry0.82Extrinsic Value100Contract SizeAmericanOptions Type0.0453Delta0.0034Gamma489.78Leverage Ratio-0.0486Theta0.0080Rho22.19Eff Leverage0.0641Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet